Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endogenous Markers for CYP3A Activity Assessment
NCT02579434Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of midazolam (4 arms), sponsored by Seoul National University Hospital. Primary endpoints: Area under the curve of midazolam (AUC12h) at 12 hours, Metabolic ratio of steroids at 12 hours and 1 more. Started Dec 2014; status: completed.
02
Drugs
midazolam
Beyond the preview
Go deeper on NCT02579434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579434.